Group 1 - The company held its fifth board meeting on September 15, 2025, where all nine directors attended and approved the proposal to use temporarily idle raised funds for cash management [2][3] - The board approved the use of up to 600 million RMB of temporarily idle A-share raised funds to purchase low-risk, high-liquidity principal-protected financial products, with a usage period of 12 months from the date of approval [7][15] - The company has previously used idle raised funds for cash management, with a total of 1,655.61 million RMB utilized as of July 31, 2025, and has received 66.34 million RMB in returns from these investments [8][10] Group 2 - The company aims to improve the efficiency of idle raised funds and increase financial returns through investments in short-term, low-risk financial products [11][14] - The investment will be managed by the company's management team, with the finance department responsible for specific operations [11][15] - The company will ensure that the investment does not affect the normal construction of fundraising projects and daily operational needs [14]
凯莱英医药集团(天津)股份有限公司 第五届董事会第三次会议决议的公告